DrugPatentWatch Database Preview
COREG CR Drug Profile
Email this page to a colleague
See Plans and PricingWhich patents cover Coreg Cr, and when can generic versions of Coreg Cr launch?
Coreg Cr is a drug marketed by Smithkline Beecham and is included in one NDA. There are two patents protecting this drug and three Paragraph IV challenges.
This drug has fifty-one patent family members in seventeen countries.
The generic ingredient in COREG CR is carvedilol phosphate. There are thirty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.
US ANDA Litigation and Generic Entry Outlook for Coreg Cr
A generic version of COREG CR was approved as carvedilol phosphate by SUN PHARM INDUSTRIES on October 25th, 2017.
Summary for COREG CR
| International Patents: | 51 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 114 |
| Patent Applications: | 4,323 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for COREG CR |
| Drug Sales Revenues: | Drug sales revenues for COREG CR |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for COREG CR |
| DailyMed Link: | COREG CR at DailyMed |
Recent Litigation for COREG CR
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| GlaxoSmithKline LLC v. Glenmark Pharmaceuticals Inc., USA | 2014-07-03 |
| GlaxoSmithKline LLC v. Teva Pharmaceuticals USA Inc. | 2014-07-03 |
| FLAMEL TECHNOLOGIES S.A. v. LUPIN LIMITED | 2011-05-04 |
Pharmacology for COREG CR
| Drug Class | alpha-Adrenergic Blocker beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists Adrenergic beta1-Antagonists Adrenergic beta2-Antagonists |
Synonyms for COREG CR
| (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol |
| (+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol |
| [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine |
| 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol |
| 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol |
| 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol |
| 102641-EP2270011A1 |
| 102641-EP2272841A1 |
| 102641-EP2275420A1 |
| 102641-EP2298764A1 |
| 102641-EP2298765A1 |
| 102641-EP2301936A1 |
| 107741-96-8 |
| 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)- |
| 72956-09-3 |
| 956C093 |
| AB0008431 |
| AB00639903_10 |
| AB00639903_11 |
| AB00639903_12 |
| AB00639903-07 |
| AB00639903-09 |
| AB1004830 |
| AC-1641 |
| AC1L1E0B |
| AKOS005554967 |
| AN-14749 |
| API0001873 |
| Artist |
| Artist (TN) |
| AX8120145 |
| BBL029064 |
| BC204100 |
| BCP0726000253 |
| BCP23386 |
| BCP9000493 |
| BDBM25759 |
| BG0129 |
| BM 14.190 |
| BM 14190 |
| BM-14-190 |
| BM-14.190 |
| BM-14190 |
| BRD-A10977446-001-04-8 |
| BRD-A10977446-001-05-5 |
| BRD-A10977446-045-01-1 |
| C-21835 |
| C06875 |
| C24H26N2O4 |
| carvedilol |
| Carvedilol (JAN/USAN/INN) |
| Carvedilol [USAN:INN:BAN:JAN] |
| Carvedilol [USAN:USP:INN:BAN:JAN] |
| Carvedilol 1.0 mg/ml in Methanol |
| Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard |
| Carvedilol, >=98% (HPLC), solid |
| Carvedilol, European Pharmacopoeia (EP) Reference Standard |
| Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material |
| Carvedilol, United States Pharmacopeia (USP) Reference Standard |
| Carvedilolum |
| Carvedilolum [Latin] |
| CC-25436 |
| CCG-100917 |
| CCG-207952 |
| CHEBI:3441 |
| CHEMBL723 |
| Coreg |
| Coreg (TN) |
| Coropress |
| CPD000449280 |
| CS-1194 |
| CTK3J2232 |
| D00255 |
| DB01136 |
| Dibloc |
| Dilatrend |
| DQ 2466 |
| DQ-2466 |
| DTXSID8022747 |
| EG-P042 |
| Eucardic |
| FT-0603059 |
| FT-0652640 |
| GTPL551 |
| HMS2051N03 |
| HMS2089B09 |
| HMS2093E12 |
| HMS3261E15 |
| HMS3269N11 |
| HMS3393N03 |
| HMS3655O14 |
| HMS3715D15 |
| HSDB 7044 |
| HY-B0006 |
| I06-0064 |
| I06-1477 |
| J10039 |
| KB-75594 |
| KBio2_002145 |
| KBio2_004713 |
| KBio2_007281 |
| KBio3_002323 |
| KBioGR_001252 |
| KBioSS_002145 |
| Kredex |
| KS-00000XRT |
| KS-1037 |
| KSC492E3F |
| L001243 |
| LP00347 |
| LS-121875 |
| MCULE-7944987271 |
| MFCD00864692 |
| MLS000758299 |
| MLS000759508 |
| MLS001424092 |
| MLS006011886 |
| MolPort-003-666-814 |
| NC00167 |
| NCGC00167832-01 |
| NCGC00167832-02 |
| NCGC00167832-03 |
| NCGC00167832-04 |
| NCGC00261032-01 |
| NSC-758694 |
| NSC758694 |
| OGHNVEJMJSYVRP-UHFFFAOYSA-N |
| Pharmakon1600-01504257 |
| PubChem18218 |
| Q-200801 |
| Querto |
| RTR-037608 |
| s1831 |
| SAM001246736 |
| SAM001247021 |
| SB17441 |
| SBI-0206771.P001 |
| SC-13445 |
| SCHEMBL10082334 |
| SCHEMBL13287211 |
| SCHEMBL22293 |
| SK&F-105517 |
| SKF 105517 |
| SMR000449280 |
| SPBio_001885 |
| Spectrum_001665 |
| Spectrum2_001673 |
| Spectrum3_001182 |
| Spectrum4_000636 |
| Spectrum5_001436 |
| SR-01000759289 |
| SR-01000759289-5 |
| SR-01000759289-6 |
| SR-01000759289-9 |
| ST24036957 |
| STK621453 |
| SW197547-3 |
| TL8005080 |
| Tox21_500347 |
| TR-037608 |
| W-5131 |
| Z2786051695 |
Paragraph IV (Patent) Challenges for COREG CR
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| COREG CR | CAPSULE, EXTENDED RELEASE;ORAL | carvedilol phosphate | 022012 | 2008-03-18 |
| COREG CR | CAPSULE, EXTENDED RELEASE;ORAL | carvedilol phosphate | 022012 | 2007-12-21 |
| COREG CR | CAPSULE, EXTENDED RELEASE;ORAL | carvedilol phosphate | 022012 | 2007-11-19 |
US Patents and Regulatory Information for COREG CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | AB | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COREG CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-002 | Oct 20, 2006 | Start Trial | Start Trial |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | Start Trial | Start Trial |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-001 | Oct 20, 2006 | Start Trial | Start Trial |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-003 | Oct 20, 2006 | Start Trial | Start Trial |
| Smithkline Beecham | COREG CR | carvedilol phosphate | CAPSULE, EXTENDED RELEASE;ORAL | 022012-004 | Oct 20, 2006 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COREG CR
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1976682 | Start Trial |
| Canada | 2492060 | Start Trial |
| South Korea | 20040073433 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2005099671 | Start Trial |
| Brazil | 0213175 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
